EDITORIAL COMMENT

# The Sum of Two Evils

Pneumonia and Myocardial Infarction: Is Platelet Activation the Missing Link?\*

Carlos G. Santos-Gallego, MD, Juan J. Badimon, PHD

ommunity-acquired pneumonia (CAP) affects >5 million adults, causes 1.1 million hospital admissions, and is responsible for >60,000 deaths each year in the United States (1). Recent studies connected CAP with cardiovascular disease (CVD), the leading cause of death worldwide (2), and its most feared complication, myocardial infarction (MI). In this issue of the *Journal*, Cangemi et al. (3) add a new piece to the puzzle of this relationship.

#### SEE PAGE 1917

Although traditionally regarded as confined to the lungs, all severities of acute pneumonia infection affect the cardiovascular system. Several recent retrospective clinical observations and meta-analyses found increased MI incidence after CAP (see Corrales-Medina et al. [1] for a comprehensive summary). Analysis of a prospective multicenter cohort of 2,344 unselected patients with CAP confirmed these data (4). In this cohort, 30-day incidences of heart failure, arrhythmia, and MI were 21%, 10%, and 3%, respectively, with risks peaking in the first 2 days of hospitalization. Even after adjusting for baseline risk, MI was independently associated with a 60% increase in short-term mortality risk. These findings suggest that prevention of cardiac complications may improve CAP outcomes.

This increased MI risk is not limited to CAP. Large retrospective epidemiological studies found increased MI risk after acute respiratory infections (5), and retrospective studies (6) and clinical trials (7) showed an association between influenza vaccination and reduced risk for MI and stroke. Additionally, early treatment of influenza in patients with CVD was associated with a 60% decrease in MI risk (8).

Despite this robust association, its potential mechanisms of action are not well understood, although several hypotheses have been postulated. Atherosclerosis is an inflammatory disease; acute infections, such as CAP, not only elicit systemic inflammatory responses but can also have direct inflammatory effects on atherosclerotic plaques, increasing their vulnerability. In atherosclerotic apolipoprotein E-knockout mice, influenza virus infection promotes acute inflammation in the atheromata (infiltration of plaques with macrophages and T lymphocytes) and superimposed fibrin deposition, similar to unstable plaques after MI (9). Coronary artery tone abnormalities may also be involved, as increased vasoconstrictive responses were observed in animals injected with staphylococcal  $\alpha$ -toxins (10). Other factors may likely contribute: tachycardia shortens diastole (when coronary perfusion occurs), decreased central blood pressure (as in severe sepsis) impairs myocardial perfusion through stenotic coronary segments, and hypoxemia and increased cardiac metabolic demands (secondary to tachycardia and catecholamine release) can contribute to the development of myocardial ischemia.

The work of Cangemi et al. (3) is a prospective study in which 278 consecutive patients with CAP at 4 different hospitals were recruited and followed until discharge, including periodic cardiac (high-sensitivity cardiac troponin T [hs-cTnT]) and in vivo platelet activation marker measurement. Although up to 52% of patients with CAP had high hs-cTnT levels, 11% of them showed signs of MI (increased hs-cTnT concentrations and electrocardiographic changes or symptoms). Thus, in the 41% of patients without

<sup>\*</sup>Editorials published in the *Journal of the American College of Cardiology* reflect the views of the authors and do not necessarily represent the views of *JACC* or the American College of Cardiology.

From the Atherothrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose.

electrocardiographic changes, increased hs-cTnT is probably not secondary to ischemia. Other possibilities include stress-induced cardiomyopathy or nonspecific toxic effects on cardiomyocytes, leading to biomarker leakage. The 11% MI rate was higher than in previous reports, probably explained by the use of hs-cTnT instead of creatine kinase (4), a less sensitive myocardial injury biomarker, and because hs-cTnT levels were measured every 12 h, not only at hospital admission (4). The main clinical takehome message is that patients with previous CVD or severe CAP (both independently associated with MI) should be monitored daily with hs-cTnT and electrocardiographic assessment to detect MI, especially during the first 2 days of hospitalization, because MI was asymptomatic and increased the risk for death.

This paper's importance stems from its suggestion that high platelet activation may provide a mechanistic explanation for increased MI risk in CAP. In vivo platelet activation markers (soluble CD40 ligand, soluble P-selectin, and thromboxane  $B_2$  levels) at admission were increased in patients who subsequently developed MIs, suggesting that CAP increases platelet activation, which may in turn cause MI. Previous studies highlighted the contribution of infection to platelet activation. Kreutz et al. (11) found increased platelet reactivity in patients affected by viral respiratory infections compared with healthy controls. Modica et al. (12) found more pronounced platelet aggregation and increased aspirin nonresponsiveness in patients with MIs with concurrent infection than in uninfected patients with MIs. Several mechanisms were proposed to explain these findings. Gram-positive bacteria induce platelet aggregation and the formation of platelet-neutrophil complexes (13). Additionally, in response to lipopolysaccharide from Gram-negative bacteria, platelets bind more avidly to fibrinogen under flow conditions in a Toll-like receptor 4-dependent manner (14). Surprisingly, Cangemi et al. (3) found no difference in the MI rate between aspirin-treated and untreated patients.

A limitation of the present study is that the role of platelet function is not fully understood. Platelet aggregation may be either a risk factor (it correlates with the disease, and treatment reduces the incidence of the disease) or a risk marker (it correlates with the disease, but treatment does not affect the incidence of the disease because it is merely a surrogate indicator of disease severity). Platelet aggregation seems to behave as a risk marker. In the GRAVITAS (Gauging Responsiveness With a VerifyNow Assay-Impact on Thrombosis and Safety) (15) and ARCTIC (Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy; NCT00827411) (16) clinical trials, tailored pharmacological antiplatelet therapy aiming to decrease platelet aggregation did not reduce CVD events. Therefore, increased platelet activation in CAP may be a marker of disease severity but not a causal link, and antiplatelet therapy would not reduce MI. That aspirin-treated patients did not show reduced MI risk in this population supports this notion, as does the lack of a statistically significant reduction in MI among aspirin-treated patients with CAP in previous observational studies (17,18). Alternatively, because platelet aggregation involves many different agonists (arachidonic acid/thromboxane A2 receptors, adenosine diphosphate/P2Y12 receptors, von Willebrand factor/glycoprotein Ib, collagen/glycoprotein VI, glycoprotein IIb/IIIa, thrombin/thrombin receptor), specific inhibition of a single pathway (thromboxane A2, with aspirin) may be insufficient to mitigate MI risk. An open question is whether patients with CAP should be treated prophylactically with more potent antiplatelet therapy.

The study by Cangemi et al. (3) confirms high MI incidence during CAP (silent MI in the first 2 days of hospitalization, especially in patients with severe CAP or previous CVD) and suggests CAP-mediated increased platelet activation as the mechanistic explanation but still leaves some questions unanswered. Future studies are needed for confirmation of the mechanism and to delineate the best therapy (e.g., antiplatelet agents, vaccines) to reduce MI risk.

**REPRINT REQUESTS AND CORRESPONDENCE:** Dr. Juan J. Badimon, Atherothrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, New York 10029. E-mail: juan.badimon@mssm.edu.

#### REFERENCES

**1.** Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010;10:83-92.

**2.** Roger VL, Go AS, Lloyd-Jones DM, et al., American Heart Association Statistics Committee and Stroke

Statistics Subcommittee. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220.

**3.** Cangemi R, Casciaro M, Rossi E, et al., for the SIXTUS Study Group. Platelet activation is associated

with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 2014;64:1917-25.

**4.** Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with communityacquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125:773-81.

**5.** Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-8.

**6.** Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003;348:1322-32.

7. Gurfinkel EP, de la Fuente RL, Mendiz O, et al. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002; 105:2143-7.

**8.** Casscells SW, Granger E, Kress AM, et al. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardio-vascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ Cardiovasc Qual Outcomes 2009;2:108–15.

**9.** Naghavi M, Wyde P, Litovsky S, et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques

of apolipoprotein E-deficient mice. Circulation 2003;107:762-8.

**10.** Sibelius U, Grandel U, Buerke M, et al. Staphylococcal alpha-toxin provokes coronary vasoconstriction and loss in myocardial contractility in perfused rat hearts: role of thromboxane generation. Circulation 2000;101:78–85.

**11.** Kreutz RP, Tantry US, Bliden KP, et al. Inflammatory changes during the "common cold" are associated with platelet activation and increased reactivity of platelets to agonists. Blood Coagul Fibrinolysis 2007;18:713–8.

**12.** Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 2007;5:507-11.

**13.** Johansson D, Shannon O, Rasmussen M. Platelet and neutrophil responses to Gram positive pathogens in patients with bacteremic infection. PLoS One 2011;6:e26928.

**14.** Andonegui G, Kerfoot SM, McNagny K, et al. Platelets express functional Toll-like receptor-4. Blood 2005;106:2417-23. **15.** Price MJ, Berger PB, Teirstein PS, et al., GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305: 1097-105.

**16.** Collet JP, Cuisset T, Range G, et al., ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9.

**17.** Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008;121:1002-7.e1.

**18.** Winning J, Reichel J, Eisenhut Y, et al. Antiplatelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009;20:50-7.

**KEY WORDS** atherosclerotic, cardiovascular disease, human, inflammation, plaque, prospective studies, risk factors

## Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia



Roberto Cangemi, MD,\* Marco Casciaro, MD,\* Elisabetta Rossi, MD,\* Camilla Calvieri, MD,† Tommaso Bucci, MD,\* Cinzia Myriam Calabrese, MD,\* Gloria Taliani, MD,‡ Marco Falcone, MD,§ Paolo Palange, MD,§ Giuliano Bertazzoni, MD,|| Alessio Farcomeni, PHD,§ Stefania Grieco, MD,‡ Pasquale Pignatelli, MD,\* Francesco Violi, MD,\* in collaboration with the SIXTUS Study Group

## ABSTRACT

**BACKGROUND** Troponins may be elevated in patients with pneumonia, but associations with myocardial infarction (MI) and with platelet activation are still undefined.

**OBJECTIVES** The aim of this study was to investigate the relationship between troponin elevation and in vivo markers of platelet activation in the early phase of hospitalization of patients affected by community-acquired pneumonia.

**METHODS** A total of 278 consecutive patients hospitalized for community-acquired pneumonia, who were followed up until discharge, were included. At admission, platelet activation markers such as plasma soluble P-selectin, soluble CD40 ligand, and serum thromboxane B<sub>2</sub> (TxB<sub>2</sub>) were measured. Serum high-sensitivity cardiac troponin T levels and electrocardiograms were obtained every 12 and 24 h, respectively.

**RESULTS** Among 144 patients with elevated high-sensitivity cardiac troponin T, 31 had signs of MI and 113 did not. Baseline plasma levels of soluble P-selectin and soluble CD40 ligand and serum  $TxB_2$  were significantly higher in patients who developed signs of MI. Logistic regression analysis showed plasma soluble CD40 ligand (p < 0.001) and soluble P-selectin (p < 0.001), serum  $TxB_2$  (p = 0.030), mean platelet volume (p = 0.037), Pneumonia Severity Index score (p = 0.030), and ejection fraction (p = 0.001) to be independent predictors of MI. There were no significant differences in MI rate between the 123 patients (45%) taking aspirin (100 mg/day) and those who were not aspirin treated (12% vs. 10%; p = 0.649). Aspirin-treated patients with MIs had higher serum  $TxB_2$  compared with those without MIs (p = 0.005).

**CONCLUSIONS** MI is an early complication of pneumonia and is associated with in vivo platelet activation and serum TxB<sub>2</sub> overproduction; aspirin 100 mg/day seems insufficient to inhibit thromboxane biosynthesis. (MACCE in Hospitalized Patients With Community-acquired Pneumonia; NCT01773863) (J Am Coll Cardiol 2014;64:1917-25) © 2014 by the American College of Cardiology Foundation.

ommunity-acquired pneumonia (CAP) is the most common infection leading to hospitalization in intensive care units and the most common cause of death associated with infectious diseases (1). Epidemiological studies have shown that respiratory tract infections are associated with

#### SEE PAGE 1926

an increased risk for the development of acute cardiovascular events (2). This link is further supported by studies indicating that influenza vaccination is associated with reduced risk for

From \*I Clinica Medica, Sapienza University of Rome, Rome, Italy; †Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, Sapienza University of Rome, Rome, Italy; †Department of Public Health and Infectious Diseases Unit, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy; \$Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy; and the ||UOC Emergency Medicine, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy. See the Appendix for a list of the members of the SIXTUS Study Group. This work was supported by a grant from Sapienza University of Rome (Progetto Universitario 2010) to Prof. Violi. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received April 18, 2014; revised manuscript received June 17, 2014, accepted July 8, 2014.

#### ABBREVIATIONS AND ACRONYMS

ASA = acetylsalicylic acid

CAP = community-acquired pneumonia

CHD = coronary heart disease

COPD = chronic obstructive pulmonary disease

hs-cTnT = high-sensitivity cardiac troponin T

IQR = interquartile range

MI = myocardial infarction

MPV = mean platelet volume

PAD = peripheral arterial disease

PSI = Pneumonia Severity Index

sCD40L = soluble CD40 ligand

sP-selectin = soluble p-selectin

T2DM = type 2 diabetes mellitus

TxB<sub>2</sub> = thromboxane B<sub>2</sub>

hospitalization for pneumonia, heart disease, cerebrovascular disease, and the risk for death from all causes during influenza seasons in elderly patients (3).

A prospective study (4) focused attention on the association of pneumonia with elevations of cardiac enzymes (e.g., creatine kinase-MB) and signs of myocardial ischemia, suggesting that myocardial infarction (MI) may be a complication of pneumonia in the early phase of clinical presentation. More recently, Chang et al. (5) showed elevated serum troponins (a more sensitive marker of cardiac damage than creatine kinase-MB) in patients with pneumonia, but the relationship with MI was not investigated. Furthermore, the mechanism of MI in patients with pneumonia is still elusive.

Platelets play a key role in the occurrence of MI, as shown by interventional trials showing that acetylsalicylic acid (ASA), which inhibits platelet thromboxane A2 production via irreversible acetylation of COX-1 (6), lowers cardiovascular events in patients with acute or chronic coronary heart disease (CHD) (7). In patients with pneumonia or other infections, previous studies showed in vivo elevation of platelet activation biomarkers, suggesting potential interplay between platelet overactivation and cardiovascular events during pneumonia. Thus, we speculated that in pneumonia, differences in platelet activation might be detected in patients with and without signs of MI. For this purpose, we performed a prospective study in which the relationships between in vivo markers of platelet activation were analyzed in the early phase of hospitalization of patients affected by CAP. Markers analyzed included plasma levels of soluble CD40 ligand (sCD40L) (8) and soluble Pselectin (sP-selectin) (9); serum levels of thromboxane B<sub>2</sub> (TxB<sub>2</sub>), which reflects maximal platelet formation of thromboxane A2 (10-12); and serum levels of high-sensitivity cardiac troponin T (hscTnT).

## METHODS

**PATIENT SELECTION.** The study was conducted at 4 centers of the University Hospital Policlinico Umberto I (Rome, Italy). All patients with CAP admitted to the 4 units through the emergency department from October 2011 to April 2013 were prospectively recruited and followed up. After they gave written informed consent, we enrolled 278 consecutive patients who fulfilled the following

criteria in the study: 1) age  $\geq$  18 years; 2) clinical presentation of an acute illness with one or more of the following signs or symptoms suggesting CAP: presence of rales, rhonchi, bronchial breath sounds, dullness, increased fremitus and egophony, fever (>38.0°C), tachycardia, chills, dyspnea, coughing (productive or unproductive cough), and chest pain; and 3) presence of new consolidation(s) on chest x-ray. Pneumonia was considered CAP if it was diagnosed on hospitalization and the patient had not been discharged from an acute care facility within 14 days preceding the clinical presentation.

Patients were excluded from the study if any of the following criteria applied: radiographic evidence of preexisting infiltrates, severe sepsis or immunosuppression (human immunodeficiency virus infection, chemotherapy, high doses of immunosuppressive agents such as prednisone), presence of malignancy, pregnancy or breastfeeding, documented severe allergy to antibiotics, and health care-associated pneumonia (13).

BASELINE ASSESSMENT. Data on demographic characteristics and comorbidities were collected. Severity of illness at presentation was quantified by the Pneumonia Severity Index (PSI), a validated prediction score for 30-day mortality in patients with CAP (14). Immediately after diagnosis of CAP, routine blood laboratory tests including platelet count and mean platelet volume (MPV), serum hs-cTnT and high-sensitivity C-reactive protein, serum TxB<sub>2</sub>, and arterial blood gas test, were performed. Thereafter, serum hs-cTnT was assessed every 12 h, and 12-lead electrocardiography was repeated every 24 h. M-mode and 2-dimensional color Doppler echocardiography was performed within 2 days of hospital admission. Ejection fraction was measured using the modified Simpson's rule.

Type 2 diabetes mellitus (T2DM), hypertension, history of CHD, dyslipidemia, peripheral arterial disease (PAD), and chronic obstructive pulmonary disease (COPD) were defined as previously described (15-17). Baseline treatments were defined according to patients' pharmacological histories. Patients already treated with ASA before admission were categorized as ASA users. Compliance with ASA and other medications was monitored daily.

This study was conducted according to the principles stated in the Declaration of Helsinki. The institutional review board approved this prospective, observational study, which was registered at ClinicalTrials.gov (NCT01773863).

**STUDY ENDPOINTS.** The primary study end point was the occurrence of MI during the hospital stay.

MI criteria were those of the third universal definition of MI: the detection of an increase in cardiac troponin with at least 1 value above the 99th percentile upper reference limit, associated with at least 1 of the following: 1) chest pain; 2) detection of new or presumably new significant ST-segment-T-wave changes or new left bundle branch block; 3) development of pathological Q waves on electrocardiography; 4) de novo imaging evidence of viable myocardium loss or regional wall motion abnormality; 5) identification of an intracoronary thrombus by angiography or autopsy; and 6) cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic electrocardiographic changes or new left bundle branch block (18).

ST-segment elevation MI and non-ST-segment elevation MI were defined as previously reported (18). Therapeutic treatment at admission and during the hospital stay were registered.

Adjudication of cardiovascular events was performed by a committee of cardiologists (C.C. and A.C.) who did not participate in patient recruitment and follow-up and were unaware of any patient's clinical and laboratory characteristics.

**PLASMA LEVELS OF sCD4OL, sP-SELECTIN, AND SERUM TXB**<sub>2</sub>. Blood samples to measure biomarkers of platelet activation were obtained within 24 h of admission and at the end of hospitalization. Samples with or without 3.8% sodium citrate were taken without stasis from patients who had fasted for at least 12 h.

After withdrawal of a first blood sample, 1-ml serum aliquots were immediately transferred into glass tubes and allowed to clot at  $37^{\circ}$ C for 1 h. Serum was separated by centrifugation and frozen at  $-80^{\circ}$ C until assayed. Serum TxB<sub>2</sub> was measured using an enzyme-linked immunosorbent assay commercial kit (R&D Systems, Inc., Minneapolis, Minnesota) and expressed as nanograms per milliliter. Intra- and interassay coefficients of variation for the TxB<sub>2</sub> assay kit were 5.9% and 8.9%, respectively.

Citrated samples were centrifuged to separate plasma, which was frozen at  $-80^{\circ}$ C until assayed. Plasma sCD40L and sP-selectin levels were measured with a commercial immunoassay (Tema Ricerca, Castenaso, Italy). Intra- and interassay coefficients of variation were 5% and 7% for sCD40L and 4.3% and 6.1% for sP-selectin.

**SERUM HS-CTNT MEASUREMENT.** Hs-CTnT levels were measured with the Elecsys 2010 (Roche Diagnostics, Indianapolis, Indiana) at a dedicated core laboratory. According to the manufacturer, the 99th-percentile cutoff point for hs-cTnT is 0.014  $\mu$ g/l,

and a coefficient of variation of <10% is achieved at 0.013  $\mu g/l$  (19).

**STATISTICAL ANALYSIS.** Categorical variables are reported as counts and percentages and continuous variables as mean  $\pm$  SD or medians and interquartile ranges (IQRs). Differences between percentages were assessed by chi-square or Fisher exact tests. Student unpaired *t* tests and analysis of variance were used for normally distributed continuous variables. Appropriate nonparametric tests (Mann-Whitney, Kruskal-Wallis, and Spearman rank correlation tests) were used for all other variables.

To better define the relationships between TxB<sub>2</sub>, sCD40L, and sP-selectin levels and cardiovascular events, we grouped these continuous marker measurements into 4 categories, with cutoffs on the basis of quartiles of the observed measurements.

The bivariate and multivariate effects of prognostic factors and treatments on the primary and secondary endpoints were assessed by means of logistic regression models. Wald confidence intervals and tests for odds ratios and adjusted odds ratios were computed on the basis of the estimated standard errors. In addition to TxB<sub>2</sub>, sCD40L, and sP-selectin levels, possible independent variables considered were age, sex, body mass index, PSI score, ejection fraction, history of CHD or stroke, T2DM, hypertension, renal failure, COPD, chronic or paroxysmal atrial fibrillation, dyslipidemia, PAD, high-sensitivity C-reactive protein, and use of statins and ASA.


For multivariate models, model selection was performed using forward stepwise regression on the basis of the Akaike information criterion.

Variance inflation factors were computed to assess collinearity for each predictor in the final multivariate model, with a variance inflation factor < 2.5 considered safe. The variance inflation factor criterion was satisfied in all reported models, hence there were no collinearity issues.

 $TxB_2$ , sCD40L, and sP-selectin levels evaluated at the end of hospitalization were compared with baseline levels by Wilcoxon rank sum tests.

Only p values <0.05 were regarded as statistically significant. All tests were 2-tailed, and analyses were performed using computer software packages (R version 2.15.2, R Development Core Team, Vienna, Austria).

**Sample size.** The minimum sample size was computed considering 1) an expected rate of MI of 5% (20-24); 2) a relevant difference in TxB<sub>2</sub> levels to be detected between groups of  $|\delta| \ge 50$  ng/ml; 3) a SD between the groups of 35 ng/ml; and 4) type I error probability of  $\alpha = 0.05$  and power of  $1 - \beta = 0.90$ .



This resulted in a sample size of 220 patients. The expected event rate and  $TxB_2$  levels were obtained by analyzing data from previous studies (25).

Variable	CAP With hs-cTnT ≤0.014 µg/l (n = 134)	CAP With hs-cTnT >0.014 µg/l Without MI (n = 113)	CAP With hs-cTnT >0.014 µg/l and MI (n = 31)	p Value
Age, yrs	$\textbf{61.8} \pm \textbf{16.6}$	$\textbf{77.3} \pm \textbf{10.2}$	$\textbf{79.2} \pm \textbf{8.9}$	< 0.001
Men	62	65	58	0.742
BMI, kg/m <sup>2</sup>	$\textbf{26.4} \pm \textbf{4.1}$	$\textbf{26.6} \pm \textbf{3.8}$	$\textbf{26.8} \pm \textbf{3.6}$	0.875
Ejection fraction, %	$\textbf{56.4} \pm \textbf{6.2}$	$\textbf{49.7} \pm \textbf{10.4}$	$\textbf{43.9} \pm \textbf{8.6}$	< 0.001
Pre-existing comorbid conditions				
History of CHD	21	45	65	< 0.001
Previous stroke	11	9	23	0.104
T2DM	16	31	32	0.015
Hypertension	58	79	84	0.001
Renal failure	4	33	29	< 0.001
COPD	25	48	36	0.017
PAF	9	16	16	0.281
CAF	8	25	16	0.002
Peripheral artery disease	2	10	13	0.018
Dyslipidemia	17	24	29	0.231
ASA	37	52	48	0.069
Statins	32	36	37	0.776
hs-CRP, ng/ml	5.9 (2.7-12.8)	6.0 (3.3-12.7)	6.3 (3.5-11.6)	0.955
PSI score	$75 \pm 27$	$104 \pm 25$	$120\pm29$	< 0.001
Platelet count	223 (173-319)	238 (180-274)	237 (173-249)	0.767
MPV, fl	8.3 (7.5-8.8)	8.6 (7.7-9.5)	9.4 (8.2-10.4)	0.001
sCD40L, ng/ml	3 (2.2-4.0)	3.2 (2.4-6.0)	10 (9.5-13)	< 0.001
sP-selectin, ng/ml	15 (11-19)	22 (16-30)	37 (28-48)	< 0.001
TxB <sub>2</sub> , ng/ml	108 (60-200)	106 (50-180)	200 (100-352)	0.004

Values are mean  $\pm$  SD, %, or median (interquartile range).

ASA = acetylsalicylic acid; BMI = body mass index; CAF = chronic (persistent or permanent) atrial fibrillation; CAP = community-acquired pneumonia; CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease; hs-CRP = high-sensitivity C-reactive protein; hs-cTnT = high-sensitivity cardiac troponin T; MI = myocardial infarction; MPV = mean platelet volume; PAD = peripheral artery disease; PAF = paroxysmal atrial fibrillation; PSI = Pneumonia Severity Index; sCD4OL = soluble CD40 ligand; sP-selectin = soluble P-selectin; T2DM = type 2 diabetes mellitus; TXB<sub>2</sub> = thromboxane B<sub>2</sub>.

## RESULTS

We recruited 278 patients hospitalized for CAP (173 men, 105 women; mean age 70.0  $\pm$  15.7 years). Most of the patients had arterial hypertension (68%). Histories of CHD were present in 36% of patients, previous strokes in 12%, T2DM in 24%, COPD in 35%, PAD in 7%, and dyslipidemia in 21%. Histories of paroxysmal atrial fibrillation were present in 12% of patients, while 16% were affected by chronic (persistent or permanent) atrial fibrillation, and 18% had severe renal failure (i.e., glomerular filtration rate <30 ml/min). Among the entire population, 123 patients (47%) were treated with ASA 100 mg/day.

Elevated serum levels of hs-cTnT (>0.014  $\mu$ g/l; median 0.042  $\mu$ g/l; IQR: 0.024 to 0.116  $\mu$ g/l) were found in 144 of the patients with CAP (52%). Of these 144 patients, 113 had isolated hs-cTnT elevations, and 31 showed signs of MI (Figure 1). MI generally occurred within 48 h of pneumonia clinical presentation. Most MIs were non-ST-segment elevation MIs (n = 26), 2 were ST-segment elevation MIs, 3 were fatal, and all but 2 had no chest pain.

Clinical characteristics of patients with CAP without hs-cTnT elevation (median 0.010; IQR: 0.007 to 0.011  $\mu$ g/l), patients with hs-cTnT elevation (median 0.033; IQR: 0.023 to 0.060  $\mu$ g/l) without signs of MI, and patients with troponin hs-cTnT elevation (median 0.299; 0.165 to 0.556  $\mu$ g/l) and signs of MI are summarized in **Table 1**. Patients with hs-cTnT elevation (whether or not they developed MIs) were older and had a higher prevalence of COPD, chronic atrial fibrillation, PAD, renal failure, and T2DM than patients without hs-cTnT elevation.

Baseline plasma levels of sCD40L and sP-selectin, serum TxB<sub>2</sub>, and MPV were significantly higher in patients who developed signs of MI. Furthermore, plasma sP-selectin levels were higher in patients with isolated hs-cTnT but without signs of MI (p < 0.001) (Table 1). When ASA users and nonusers were considered separately, both sCD40L and sP-selectin were significantly correlated with serum TxB<sub>2</sub> in ASA users (Rs = 0.440; p < 0.001, and Rs = 0.214; p = 0.020, respectively) and nonusers (Rs = 0.269; p = 0.001, and Rs = 0.258; p = 0.001, respectively).

No significant differences in platelet count were observed in patients with normal or elevated hscTnT. Platelet count also did not correlate with markers of platelet activation or serum  $TxB_2$  (not shown).

To better define the magnitude of the relationship between markers of platelet activation and MI, patients with CAP were stratified into sCD40L, sP-selectin, and  $TxB_2$  quartiles (Figure 2). The largest number of MIs occurred in the upper quartiles of all 3 variables, corresponding to sCD40L >6.0 ng/ml, sP-selectin >26 ng/ml, and  $TxB_2$  >200 ng/ml.

In univariate analysis, age (p < 0.001), PSI score (p < 0.001), ejection fraction (p < 0.001), history of CHD (p < 0.001), previous stroke (p = 0.040), hypertension (p = 0.044), sCD40L >6.0 ng/ml (p < 0.001), sP-selectin >26 ng/ml (p < 0.001), TxB<sub>2</sub> >200 ng/ml (p = 0.003), and MPV (p = 0.001) were associated with MI occurrence. By multivariate analysis, sCD40L, sP-selectin, serum TxB<sub>2</sub>, MPV, PSI score, and ejection fraction were independently associated with MI (Table 2).


ASA AND THROMBOXANE. Among the 278 patients, 123 (45%) were treated with ASA 100 mg/day. The rate of MI was 10% in ASA-untreated patients and 12% in ASA-treated patients (p = 0.649). Patients with long-term ASA use showed lower serum TxB<sub>2</sub> levels than non-ASA-treated patients (median 61 ng/ml [IQR: 20 to 100 ng/ml] vs. 160 ng/ml [IQR: 106 to 247 ng/ml]; p < 0.001). Among ASA-untreated patients; serum TxB<sub>2</sub> levels were higher in those who experienced MIs compared with those who did not (p = 0.001). Similar findings were detected in ASA-treated patients; ASA-treated patients with MIs had higher serum TxB<sub>2</sub> values than ASA-untreated patients (p = 0.005) (Figure 3). Only 9 patients had serum TxB<sub>2</sub> <10 ng/ml, corresponding to full COX1 inhibition (26).

### FOLLOW-UP OF PLATELET ACTIVATION BIOMARKERS.

Analyses of plasma sCD40L and sP-selectin levels and serum  $TxB_2$  were repeated at the end of hospitalization (within approximately 10 days of hospital admission). Compared with baseline values, all of the variables significantly decreased, independent of ASA use (Figure 4).

## DISCUSSION

In this study, we prospectively analyzed the incidence of MI in patients hospitalized for CAP. The novel findings of the study are as follows: 1) in the early phase of pneumonia (within 48 h of presentation), patients showed elevated hs-cTnT, which may be either isolated or MI associated; 2) MI was not associated with chest pain in the majority of cases; 3) the severity of pneumonia, as assessed by PSI score and ejection fraction, was independently associated with MI; 4) in vivo platelet activation and overproduction of serum  $TxB_2$  formation were independently associated with MI; and 5) ASA 100 mg/day seemed insufficient for preventing serum  $TxB_2$ overproduction.



Previous studies showed that pneumonia is complicated by elevated hs-cTnT values, indicating an association between infectious disease and myocardial injury. Notably, Chang et al. (5) recently reported that 19% of patients with pneumonia have elevated hs-cTnT values at admission. We found that elevated hs-cTnT was even more prevalent in our population; hs-cTnT was elevated in >50%. This difference may be because we measured hs-cTnT levels not only at baseline but also every 12 h during the first days of hospitalization. Increased hs-cTnT was detectable up to 48 h from hospital admission,


TABLE 2         Adjusted ORs for MI According to Selected Variables           on the Basis of Logistic Regression Analysis									
		95% CI							
Variable	OR	Lower	Upper	p Value	VIF*				
sCD40L >6.0 ng/ml	1.234	1.147	1.327	<0.001	1.129				
sP-selectin >26 ng/ml	1.233	1.142	1.330	< 0.001	1.217				
$TxB_2 > 200 \text{ ng/ml}$	1.084	1.008	1.166	0.030	1.035				
MPV	1.025	1.002	1.048	0.037	1.056				
Ejection fraction	0.994	0.991	0.998	0.001	1.150				
PSI score	1.001	1.001	1.002	0.030	1.254				

After adjusting for age, sex, BMI, history of CHD, previous stroke, T2DM, hypertension, renal failure, COPD, CAF, PAF, PAD, dyslipidemia, platelet count, hs-CRP, use of statins, and ASA. \*Given that all VIFs are well below the cutoff, the parameters can be directly interpreted, and there are no collinearity issues. CI = confidence interval; OR = odds ratio; VIF = variance inflation factor; other

abbreviations as in Table 1.

indicating that myocardial damage should be investigated in the early phase of hospitalization.

Among patients with elevated hs-cTnT, 31 were diagnosed as affected by MI, yielding an 11% intrahospital incidence of MI. Although previous studies showed that pneumonia may be complicated by MI (2), those were mostly retrospective studies, and the rate of MI ranged from as low as 0.8% to as high as 10.7% (21-24). In the only prospective study reported thus far, Corrales-Medina et al. (4) found a 3.6% rate during a follow-up period of 7 days. In the present study, we found a higher MI rate, likely because we measured hs-cTnT, a more sensitive marker of myocardial necrosis, and because we monitored hs-cTnT values daily, along with electrocardiography. Moreover, our hospitalized patients were older, had a higher prevalence of comorbidities, and had higher PSI scores.




MI usually occurred within 48 h of clinical presentation, consistent with the study by Corrales-Medina et al. (2), who found that more than 50% of cardiovascular complications occurred within 24 h of presentation. The peculiarity of our methodological approach turned out to be particularly useful, because almost all patients with pneumonia had silent MIs; without daily monitoring of cardiac troponins and electrocardiography, it would not be possible to fully appreciate the occurrence of MI. Among the clinical variables analyzed, age, PSI score, ejection fraction, history of CHD, previous stroke, and hypertension were associated with MI. However, in multivariate analysis, only PSI and ejection fraction were independently associated with MI. Of note, patients with a mean PSI score of 120 were at higher risk for MI. Our observation of an association between MI and history of CHD in 65% of patients who experienced MI is also interesting and suggests that patients with underlying CHD are more susceptible to MI after pneumonia.


Few studies have analyzed platelet behavior in pneumonia. Patients with MI complicated by pneumonia displayed platelet hyperaggregation and nonresponse to ASA more than patients with MI without pneumonia, suggesting that lung infection could trigger platelet activation (27,28). Additionally, Kreutz et al. (29) found higher platelet aggregation in patients affected by viral upper respiratory tract infections compared with controls. The interplay between platelet activation and MI in a population affected by pneumonia had never been examined. We report for the first time that in vivo platelet activation, as assessed by plasma levels of sCD40L and sP-selectin, was independently associated with MI. TxB<sub>2</sub> overproduction accompanied in vivo platelet activation, which was also independently associated with MI. Even if this suggests a role for COX1 activation in enhancing platelet activation, platelet TxB<sub>2</sub> overproduction is unlikely to be the only mechanism for platelet activation, as serum TxB<sub>2</sub> was only weakly correlated with sCD40L and sP-selectin.

Previous studies demonstrated that an increased platelet count was more predictive of clinical outcomes in patients with CAP than leukocyte count abnormalities (30). However, we did not observe any differences in platelet count between patients with or without MIs; conversely, MPV was both significantly higher in patients with MIs and an independent predictor, consistent with previous studies showing that MPV is independently associated with MI (31).

Bacteria may activate platelets; thus, the association between pneumonia and in vivo platelet



activation is biologically plausible. In particular, bacteria-platelet interaction may occur via bacteria binding to platelets, either directly, through a bacterial surface protein, or indirectly by a plasma-bridging molecule linking bacterial and platelet surface



Cangemi, R., et al., J Am Coll Cardiol. 2014; 64(18):1917-25.

CENTRAL ILLUSTRATION Potential Mechanisms for Platelet Activation
During Pneumonia

Platelets can interact directly with bacteria or with lipopolysaccharide (LPS) (an endotoxin) on the surface of Gram-negative bacteria by a Toll-like receptor 4 (TLR4)-mediated mechanism; this results in platelet activation and aggregation and, eventually, thrombus formation. sCD40L = soluble CD40 ligand; sP-selectin = soluble P-selectin.

receptors (28). However, whether either a specific agent or the infection burden is implicated in platelet activation and, eventually, coronary thrombosis remains to be explored (28). In this context, the role of endotoxins should be examined, as there is evidence to support a role for endotoxins as platelet stimulators via Toll-like receptor 4 (32,33) (Central Illustration). An intriguing finding of the present study was that although patients on ASA treatment showed lower serum TxB<sub>2</sub> compared with nonusers, serum TxB2 in ASA-treated patients was persistently elevated, suggesting that low-dose ASA was insufficient to fully inhibit COX1. Accordingly, many patients on ASA had values of serum TxB<sub>2</sub> >10 ng/ml, while optimal long-term ASA treatment is usually associated with serum TxB<sub>2</sub> <10 ng/ml (26). Furthermore, ASA-treated patients who experienced MIs had significantly higher serum TxB<sub>2</sub> than ASA-treated patients who did not experience MIs.

Among the whole study population, 113 patients (41%) displayed elevated hs-cTnT not associated with electrocardiographic changes, which were considered isolated hs-cTnT elevation. Isolated elevation of hs-cTnT can be detected in several clinical settings not associated with MI, including infections and sepsis, and is usually considered a specific marker of

myocardial injury (34). Even if elevated hs-cTnT is a marker of poor prognosis (35), its use for diagnosis and management in settings unrelated to acute coronary syndrome is still evolving (34). Of note, with the exception of a weak correlation with sP-selectin, neither sCD40L nor serum TxB<sub>2</sub> was correlated with isolated hs-cTnT.

**STUDY LIMITATIONS.** The study had limitations and implications. Because CAP affected our population, the data cannot be extrapolated to other types of pneumonia. The mechanism accounting for platelet activation is not fully clarified by the present study; however, the correlation between serum TxB<sub>2</sub> and the 2 markers of platelet activation suggests that platelet TxB<sub>2</sub> overproduction might play a role. We also did not investigate if pneumonia was of bacterial or viral origin or if specific pathogens or systemic inflammation were responsible for platelet activation and platelet TxB<sub>2</sub> overproduction. However, acute infection per se is likely to be implicated, as in vivo platelet activation and serum TxB2 significantly decreased at hospital discharge, independent of ASA use. Finally, we have no explanation for MI being silent in patients with pneumonia, and further study should be done to clarify this phenomenon. We cannot exclude that an imbalance between myocardial oxygen supply and demand was the primary cause of MI in many of our critically ill patients (i.e., MI type 2 according to the universal definition [18]). Therefore, further study in an even larger population is needed to better appreciate the rate of MI in this setting.

An important implication of this study is that in patients with severe pneumonia, such as those with PSI scores of approximately 120, corresponding to classes IV and V (14), or prior CHD, daily monitoring of cardiac troponins and electrocardiography is necessary to detect MI, as MI was rarely associated with chest pain. Such monitoring should be done immediately after pneumonia diagnosis, as MI generally occurred within 48 h of presentation. Another important issue raised by this study is the inefficacy of ASA 100 mg/day in completely preventing serum  $TxB_2$  formation in patients with pneumonia, suggesting that this dosage does not fully inhibit COX-1. In other clinical settings, it is becoming evident that because of accelerated platelet turnover, a dose of 100 mg ASA twice daily is more effective than ASA 100 mg/day to fully prevent platelet  $TxB_2$ (36). We cannot exclude that a similar phenomenon may also occur in pneumonia and that another ASA regimen should therefore be adopted in this clinical setting. However, we cannot exclude that the persistent platelet  $TxB_2$  elevation, despite ASA treatment, observed at baseline, may result from lowered ASA bioavailability or poor compliance (37).

## CONCLUSIONS

We provide evidence that >50% of patients with pneumonia had hs-cTnT elevation, which was isolated or associated with MI in about 11% of cases. Because MI was silent in the majority of cases, daily monitoring of troponins and electrocardiography is needed for detection. Platelet activation was significantly associated with MI, suggesting a role for platelets in triggering coronary thrombosis. Daily 100mg doses of ASA were unable to prevent platelet  $TxB_2$ formation. Future studies should be done to identify a more appropriate ASA dose to fully block COX1, thus preventing serum  $TxB_2$  overproduction in patients with pneumonia.

**REPRINT REQUESTS AND CORRESPONDENCE**: Prof. Francesco Violi, I Clinica Medica, Sapienza University of Rome, Viale del Policlinico 155, Roma 00161, Italy. E-mail: francesco.violi@uniroma1.it.

### PERSPECTIVES

## COMPETENCY IN MEDICAL KNOWLEDGE:

Elderly patients are at risk for developing myocardial ischemia and infarction early in the course of CAP. Elevated platelet activation markers and thromboxane  $A_2$  generation in these patients suggest that platelets play a role in the pathogenesis of these cardiac events.

**TRANSLATIONAL OUTLOOK:** Future studies should address the safety and efficacy of administering ASA or other antiplatelet drugs to patients presenting with acute CAP.

#### REFERENCES

**1.** McCabe C, Kirchner C, Zhang H, et al. Guidelineconcordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009;169:1525-31. **2.** Corrales-Medina VF, Musher DM, Shachkina S, et al. Acute pneumonia and the cardiovascular system. Lancet 2013;381:496-505.

**3.** Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for

cardiac disease and stroke among the elderly. N Engl J Med 2003;348:1322-32.

**4.** Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with communityacquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125:773-81.

 Chang CL, Mills GD, Karalus NC, et al. Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults. PLoS One 2013;8:e62612.

**6.** FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68 Suppl: 11B-5B.

**7.** Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.

**8.** Angelico F, Alessandri C, Ferro D, et al. Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation. Diabetologia 2006;49: 1169–74.

**9.** Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003;24:2166-79.

**10.** Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-72.

**11.** Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-71.

**12.** De Caterina R, Giannessi D, Bernini W, et al. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur Heart J 1985;6:409-17.

**13.** Venditti M, Falcone M, Corrao S, et al., Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009;150:19–26.

**14.** Aujesky D, Fine MJ. The pneumonia severity index: a decade after the initial derivation and validation. Clin Infect Dis 2008;47(suppl): S133-9.

**15.** Perk J, De Backer G, Gohlke H, et al., European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.

**16.** Loffredo L, Marcoccia A, Pignatelli P, et al. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J 2007;28:608-12.

17. Rabe KF, Hurd S, Anzueto A, et al., Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–55.

**18.** Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98.

**19.** Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361:858–67.

**20.** Viasus D, Garcia-Vidal C, Manresa F, et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013;66:27-33.

**21.** Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008;47:182-7.

**22.** Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007;45: 158-65.

**23.** Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009;88:154–9.

**24.** Mandal P, Chalmers JD, Choudhury G, et al. Vascular complications are associated with poor outcome in community-acquired pneumonia. QJM 2011;104:489-95.

**25.** Pignatelli P, Di Santo S, Barilla F, et al. Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance. J Thromb Haemost 2008:6:1832-4.

**26.** Frelinger AL III, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclo-oxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006;113: 2888-96.

**27.** Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 2007;5:507-11.

**28.** Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 2006;4:445-57.

**29.** Kreutz RP, Bliden KP, Tantry US, et al. Viral respiratory tract infections increase platelet

reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness. J Thromb Haemost 2005;3: 2108–9.

**30.** Mirsaeidi M, Peyrani P, Aliberti S, et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest 2010;137: 416-20.

**31.** Martin JF, Kristensen SD, Mathur A, et al. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol 2012;9:658-70.

**32.** Berthet J, Damien P, Hamzeh-Cognasse H, et al. Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. Clin Immunol 2012;145:189-200.

**33.** Stark RJ, Aghakasiri N, Rumbaut RE. Plateletderived Toll-like receptor 4 (Tlr-4) is sufficient to promote microvascular thrombosis in endotoxemia. PLoS One 2012;7:e41254.

**34.** de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA 2013;309: 2262-9.

**35.** Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011;123: 1367–76.

**36.** Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011;4:180–7.

**37.** Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013;127:377-85.

KEY WORDS cardiovascular disease, human, platelet aggregation, prospective studies, risk factors

APPENDIX The members of the SIXTUS Study Group are: Fabiana Albanese, MD, Elisa Biliotti, MD, Roberto Carnevale, PHD, Elisa Catasca, MD, Andrea Celestini, MD, Rozenn Esvan, MD, Lucia Fazi, MD, Paolo Marinelli, MD, Michela Mordenti, MD, Laura Napoleone, MD, Michela Palumbo, MD, Daniele Pastori, MD, Ludovica Perri, MD, Marco Proietti, MD, Rivano Capparuccia Marco, MD, Alessandro Russo, MD, Roberta Russo, MD, Valentino Sarallo, MD, Gabriele Salvatori, MD, Maria Gabriella Scarpellini, MD, and Ines Ullo, MD.